Neurology Central

Azeliragon fails Phase III trial for Alzheimer’s disease: industry news round-up

In this week’s industry news round-up we set the focus on Alzheimer’s disease (AD), with yet another clinical trial termination announced from vTv Therapeutics Inc. (NC, USA). On the other hand, Alzheimer’s researchers have proposed a novel framework for defining the disease, which focuses more on biological changes than clinical symptoms.
Find out more in our selected highlights:
  • New framework proposed for defining Alzheimer’s disease
  • Azeliragon fails in Phase III trial for Alzheimer’s disease
    Restricted Content / Members Only

    You cannot view this content because It is available to members only. Please or Register to view this area.